Journal article · 2022 · Open access

Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives

Aniek Dane, Soedaba Ashraf, James Kenneth Timmis, Monique E.M.M. Bos, Carin A. Uyl‐de Groot, P.H.M. van der Kuy

BMJ Open, 12(2), e055165 · Published 1 February 2022 · DOI 10.1136/bmjopen-2021-055165

Open PDFView at the publisherCite this paper

In brief

“Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives” is a 2022 journal article by Aniek Dane and 5 co-authors, published in BMJ Open. OpenAlex counts 6 citations as of 22 November 2026, which puts it in the top 8% of works published in 2022 by citations. It is open access under a CC BY-NC licence: the full text is free to read at BMJ Open.

Citations
6
Most cited in
2023 (2)
Field-weighted impact
0.68
References
30
Authors
6

Abstract

OBJECTIVES: Phase III cancer clinical trials are expensive and time-consuming phases in drug development. Effective patient enrolment can reduce delays and save costs, offering patients an opportunity to benefit from innovative treatments. However, the current evidence base does not fully explain the persistence of barriers to patient enrolment in phase III cancer clinical trials. The aim was to explore clinicians' and pharmaceutical representatives' views on these barriers. DESIGN: A qualitative study was performed. In-depth information was collected from 15 experts in the field of oncology clinical trials, in particular clinical oncologists acting as principal investigators (PIs) and clinical research associates. By means of semistructured interviews, based on a questionnaire derived from our newly developed conceptual framework, they were asked to identify barriers to patient enrolment they had experienced and comment on barriers identified in literature. FINDINGS: Existing knowledge on barriers to patient enrolment was confirmed by all interviewees. Two new key barriers to patient enrolment were identified, that is, insufficient attention to the importance of clinical trial-based research in medical training and a trust gap between PIs and pharmaceutical representatives. A third important barrier was increasingly narrow patient inclusion criteria. CONCLUSIONS: The success rate of patient enrolment in phase III cancer clinical trials highly depends on the clinicians' willingness to take part in clinical trials. Raising awareness of the importance of clinical trials in medical training and among practising oncologists is recommended. Furthermore, to reduce barriers to patient enrolment, it is essential that both clinicians and pharmaceutical representatives acknowledge each other's expertise, become acquainted with each other's procedures and regulations, and work on building trust relationships. Finally, in accordance with our key findings, we propose to add two new barriers to our newly developed conceptual framework; insufficient attention to clinical trial research in medical training and trust gap.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Dane, A., Ashraf, S., Timmis, J. K., Bos, M. E., Groot, C. A. U., & van der Kuy, P. (2022). Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives. BMJ Open, 12(2), e055165. https://doi.org/10.1136/bmjopen-2021-055165

MLA 9

Dane, Aniek, et al. “Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives.” BMJ Open, vol. 12, no. 2, 2022, p. e055165. https://doi.org/10.1136/bmjopen-2021-055165.

Chicago

Dane, Aniek, Soedaba Ashraf, James Kenneth Timmis, Monique E.M.M. Bos, Carin A. Uyl‐de Groot, and P.H.M. van der Kuy. 2022. “Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives.” BMJ Open 12 (2): e055165. https://doi.org/10.1136/bmjopen-2021-055165.

Harvard

Dane, A. et al. (2022) ‘Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives’, BMJ Open, 12(2), p. e055165. doi:10.1136/bmjopen-2021-055165.

IEEE

A. Dane, S. Ashraf, J. K. Timmis, M. E. Bos, C. A. U. Groot, and P. van der Kuy, “Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives,” BMJ Open, vol. 12, no. 2, p. e055165, 2022, doi: 10.1136/bmjopen-2021-055165.

BibTeX

@article{dane2022barriers,
  title     = {{Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives}},
  author    = {Dane, Aniek and Ashraf, Soedaba and Timmis, James Kenneth and Bos, Monique E.M.M. and Groot, Carin A. Uyl‐de and van der Kuy, P.H.M.},
  journal   = {BMJ Open},
  year      = {2022},
  volume    = {12},
  number    = {2},
  pages     = {e055165},
  doi       = {10.1136/bmjopen-2021-055165},
  url       = {https://doi.org/10.1136/bmjopen-2021-055165}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202322
202422
202622

Its field-weighted citation impact is 0.68: it has been cited 0.68 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research

  • patient enrollment
  • cancer clinical trials
  • principal investigators
  • trust gap
  • patient inclusion criteria
  • conceptual framework

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Dane, A., Ashraf, S., Timmis, J. K., Bos, M. E., Groot, C. A. U., & van der Kuy, P. (2022). Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives. BMJ Open, 12(2), e055165. https://doi.org/10.1136/bmjopen-2021-055165

How many times has this paper been cited?

6 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at BMJ Open: sign in and open the PDF from this page.

Who wrote this paper?

Aniek Dane, Soedaba Ashraf, James Kenneth Timmis, Monique E.M.M. Bos, Carin A. Uyl‐de Groot, P.H.M. van der Kuy.

What is the DOI of this paper?

10.1136/bmjopen-2021-055165, permanently at https://doi.org/10.1136/bmjopen-2021-055165. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.